Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Posaconazole Salvage Therapy: The Posifi Study

(2019) Jesús Fortun et al.   MYCOSES

Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation

(2017) Michaela Döring et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

FungiScope™ -Global Emerging Fungal Infection Registry

(2017) Danila Seidel et al.   MYCOSES

Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates

(2017) Jesús Guinea et al.   PLoS One

Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries

(2016) Zoi Dorothea Pana et al.   BMC INFECTIOUS DISEASES

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

(2016) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection

(2016) Jong Hun Kim et al.   MYCOSES

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies

(2015) Aaron Cumpston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis

(2015) F. Lanternier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

(2015) Oliver A. Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Review of the New Delayed-Release Oral Tablet and Intravenous Dosage Forms of Posaconazole

(2015) Anthony J. Guarascio et al.   PHARMACOTHERAPY

Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease

(2014) Johan Maertens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

(2014) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

In VitroAntifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries

(2014) P.E. Verweij et al.   JOURNAL OF CHEMOTHERAPY

Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension

(2012) Gopal Krishna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mucormycosis treated with posaconazole: review of 96 case reports

(2012) Joerg J. Vehreschild et al.   CRITICAL REVIEWS IN MICROBIOLOGY

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

(2012) G. Krishna et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database

(2010) Dimitrios P. Kontoyiannis et al.   CLINICAL INFECTIOUS DISEASES

Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B

(2010) Amar Safdar et al.   MEDICINE

Recent Advances in the Management of Mucormycosis: From Bench to Bedside

(2009) Brad Spellberg et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of antifungals against Zygomycetes

(2009) A. Alastruey-Izquierdo et al.   CLINICAL MICROBIOLOGY AND INFECTION

Forty-one recent cases of invasive zygomycosis from a global clinical registry

(2009) M. J. G. T. Ruping et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES

Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis

(2008) Georgios Chamilos et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES